PRESS RELEASES

Date Title and Summary View
Aug 7, 2014
Summary ToggleZafgen to Host Conference Call to Discuss Second Quarter 2014 Financial Results Summary ToggleZafgen to Host Conference Call to Discuss Second Quarter 2014 Financial Results
Jul 10, 2014
Summary ToggleZafgen Granted Orphan Drug Designation in the European Union for Beloranib, a First-in-Class MetAP2 Inhibitor for the Treatment of Prader-Willi Syndrome Summary ToggleZafgen Granted Orphan Drug Designation in the European Union for Beloranib, a First-in-Class MetAP2 Inhibitor for the Treatment of Prader-Willi Syndrome
Jul 1, 2014
Summary ToggleZafgen Appoints Patrick Loustau as President

Mr. Loustau Brings Over 20 Years of US and Global Management Experience

Summary ToggleZafgen Appoints Patrick Loustau as President
Jun 26, 2014
Summary ToggleZafgen Appoints New Member of Board of Directors

Mr. Thomas Brings Broad Industry Leadership Experience

Summary ToggleZafgen Appoints New Member of Board of Directors
Jun 24, 2014
Summary ToggleZafgen, Inc. Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option Summary ToggleZafgen, Inc. Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option
Jun 18, 2014
Summary ToggleZafgen, Inc. Announces Pricing of Initial Public Offering Summary ToggleZafgen, Inc. Announces Pricing of Initial Public Offering
Apr 23, 2014
Summary ToggleOxford Finance and MidCap Financial Close $20 Million Senior Credit Facility with Zafgen Summary ToggleOxford Finance and MidCap Financial Close $20 Million Senior Credit Facility with Zafgen
Feb 28, 2014
Summary ToggleZafgen Announces Support of NORD in Observing Rare Disease Day Summary ToggleZafgen Announces Support of NORD in Observing Rare Disease Day
Jan 15, 2014
Summary ToggleZafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome

Beloranib trial demonstrates improvements in body composition and cardiovascular risk factors in the largest placebo-controlled, double-blind, randomized multiple dose trial performed for obesity to date in patients with Prader-Willi syndrome

Summary ToggleZafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome
Jan 9, 2014
Summary ToggleZafgen Appoints Chief Commercial Officer and New Member of Board of Directors

- Industry Veterans Bring a Wealth of Commercial and Business Development Experience -

Summary ToggleZafgen Appoints Chief Commercial Officer and New Member of Board of Directors